Showing results (1551-1560 of 2,171) with videos related to

Sort By:
Pageof 218
Circulation|September 20, 2000
Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II InvestigatorsY Fu, W C Chang, D Mark, et al.
Therapeutic Drug Monitoring|January 8, 1998
Pitfalls in monitoring tacrolimus (FK 506)F Braun, E Schütz, U Christians, et al.
American Heart Journal|April 16, 1998
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromesE Braunwald, A Maseri, P W Armstrong, et al.
Journal of the American Academy of Dermatology|July 28, 2016
From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritisYoung M Choi, Maya Debbaneh, Jeffrey M Weinberg, et al.
European Heart Journal|October 18, 2007
Cardiovascular disease on a global scale: defining the path forward for research and practiceDaniel B Mark, Frans J Van de Werf, R John Simes, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 9, 2020
The Impact of the COVID-19 Pandemic on Ophthalmic Care at an Eye-Specific Emergency Department in an Outbreak HotspotJade Y Moon, John B Miller, Raviv Katz, et al.
The American Journal of Medicine|March 31, 2015
Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sexNaji Kholaif, Yinggan Zheng, Pushpa Jagasia, et al.
The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.
Cells|April 12, 2024
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic DermatitisKaviyon Sadrolashrafi, Lily Guo, Robin Kikuchi, et al.
American Heart Journal|September 26, 2006
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUSPeter R Sinnaeve, Yao Huang, Kris Bogaerts, et al.
Pageof 218